Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of Migraine

Key Inclusion Criteria: * Patient with at least 1-year history of migraines (with or without aura) including the following: * Migraine attacks more than 1 year with age of onset prior to 50 years of age * Migraine attacks, on average, last about 4 - 72 hours if untreated * No more than 8 attacks of moderate to severe intensity per month within last 3 months * Patient must be able to distinguish migraine attacks from tension/cluster attacks and must have consistent migraine headaches of at least 2 migraine headaches attacks of moderate to severe intensity in each of the last 3 months * Less than 15 days of headache (migraine or non-migraine) per month in each of 3 months prior to screening * Male and female ≥ 18 years and ≤ age 65 * No clinically significant abnormality identified on the medical or laboratory evaluation Key Exclusion Criteria: * Patient has a history of basilar migraine or hemiplegic migraine * Patient does not receive migraine relief from triptan migraine treatment * Medications that may alter the pH of the stomach (acid reducing agents), such as H-2 antagonists, Proton Pump inhibitors (PPI), antacids * History of ergotamine or triptan intake greater than/equal 10 days per month on a regular basis for greater than 3 months * History of non-narcotic analgesic intake on greater then/equal 15 days per month for greater than/equal 3 months

Reproduced word-for-word from the public registry record — the study team can answer questions about it.